Health Canada Has Approved Merck's Keytruda (Pembrolizumab) For Adult And Pediatric Patients With Unresectable Or Metastatic Microsatellite Instability-high Or Mismatch Repair Deficient Solid Tumors Progressed Following Prior Treatment And Who Have No Satisfactory Alternative Treatment Options
Portfolio Pulse from Benzinga Newsdesk
Health Canada has approved Merck's Keytruda for adult and pediatric patients with specific types of solid tumors that have progressed after prior treatment and have no satisfactory alternative options.
September 12, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's Keytruda has received approval from Health Canada for treating specific advanced solid tumors, potentially expanding its market and boosting sales.
The approval of Keytruda by Health Canada for additional indications can lead to increased sales and market expansion for Merck, positively impacting its stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90